ST3GAL3: A Potential Drug Target Or Biomarker (G6487)

Target Name: ST3GAL3

NCBI ID: G6487

ST3GAL3

ST3GAL3: A Potential Drug Target Or Biomarker

ST3GAL3 (OTTHUMP00000231088) is a protein that is expressed in various tissues of the body, including the liver, lung, and heart. It is a member of the GAL family of proteins, which are involved in the regulation of cellular processes such as cell adhesion, migration, and invasion.

One of the unique features of ST3GAL3 is its ability to interact with multiple intracellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cellular growth, differentiation, and survival, and is a key factor in the development and progression of many diseases.

ST3GAL3 has been shown to play a role in the regulation of TGF-β signaling in various tissues. For example, studies have shown that ST3GAL3 can inhibit the activity of the TGF-β receptor, which is involved in the regulation of cellular growth and differentiation. This suggests that ST3GAL3 may be a potential drug target or biomarker for TGF-β-related diseases.

In addition to its role in TGF-β signaling, ST3GAL3 has also been shown to be involved in the regulation of several other signaling pathways, including the PI3K/Akt signaling pathway and the NF-kappa-B signaling pathway. These pathways are involved in the regulation of cellular processes such as cell survival, angiogenesis, and inflammation, and are important for the development and maintenance of tissues and organs.

The potential utility of ST3GAL3 as a drug target or biomarker is its ability to interact with multiple signaling pathways, as well as its involvement in the regulation of cellular processes that are important for the development and maintenance of tissues and organs. This suggests that targeting ST3GAL3 may be a promising strategy for the development of new treatments for a variety of diseases.

In conclusion, ST3GAL3 is a protein that has been shown to play a role in the regulation of multiple signaling pathways, including TGF-β, PI3K/Akt, and NF-kappa-B. Its ability to interact with multiple signaling pathways makes it a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of ST3GAL3 in the regulation of cellular processes and its potential as a drug target or biomarker.

Protein Name: ST3 Beta-galactoside Alpha-2,3-sialyltransferase 3

Functions: Catalyzes the formation of the NeuAc-alpha-2,3-Gal-beta-1,4-GlcNAc-, NeuAc-alpha-2,3-Gal-beta-1,3-GlcNAc- and NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc- sequences found in terminal carbohydrate groups of glycoproteins and glycolipids. The highest activity is toward Gal-beta-1,3-GlcNAc and the lowest toward Gal-beta-1,3-GalNAc

The "ST3GAL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST3GAL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets